JP2021078495A - Composition comprising fermented soybean - Google Patents

Abstract

To provide a composition for immune suppression, for allergy symptom alleviation, allergy prevention, and cancer treatment or prevention.SOLUTION: A composition contains lactic acid bacteria-fermented soybeans, Sparassidaceae basidiomycetes and Hericiaceae basidiomycetes.SELECTED DRAWING: None

Description

Related Application This application claims the priority benefit of Provisional Application No. 62/935723 filed with the United States Patent Office on November 15, 2019. The priority basic application as a whole is made a part of this specification by specifying the source.

The present invention relates to a composition containing a fermented lactic acid bacterium of soybean, a basidiomycete of the family Sparassis crispa, and a basidiomycete of the family Hericiaceae.

Lactic acid bacteria are known to have various physiological effects, and are known to exhibit physiological activities such as intestinal regulation action and immunity improving action (Patent Documents 1 and 2). In recent years, the utility of such lactic acid bacteria has attracted widespread interest due to expectations for probiotic effects.

Further, there is disclosed a fermentation composition obtained by fermenting a mixture of beans, strawberry leaves, and basidiomycetes of the family Sparassis crispa or Hericiaceae with lactic acid bacteria (Patent Document 3). This fermentation composition is mainly related to improvement of livestock immunity, prevention of pneumonia, prevention of viral infectious diseases such as influenza, and the like.

Various compositions containing lactic acid bacteria have been studied, but more useful compositions are sought.

Japanese Unexamined Patent Publication No. 2019-116423 Japanese Unexamined Patent Publication No. 2015-177748 Japanese Unexamined Patent Publication No. 2019-182763

An object of the present invention is to provide a composition having effects such as immunosuppression, allergic symptom relief, allergy prevention, or cancer treatment or prevention.

The present inventor has found that the above-mentioned problems can be solved by a composition containing a fermented lactic acid bacterium of soybean, a basidiomycete of Sparassis crispa, and a basidiomycete of Hericiaceae, and completed the present invention.

That is, the present invention
(1) A composition containing a fermented soybean lactic acid bacterium, a basidiomycete of the Sparassis crispa family, and a basidiomycete of the Hericiaceae family.
(2) The composition of (1), in which the basidiomycete of the family Sparassis crispa is Sparassis crispa and the basidiomycete of the family Hericiaceae is Lion's mane.
(3) The composition of (1) or (2), wherein the lactic acid bacterium is a persimmon-derived lactic acid bacterium.
(4) The composition according to any one of (1) to (3), wherein the lactic acid bacterium is Lactobacillus paracasei.
(5) The composition according to any one of (1) to (4), which is for immunosuppression, allergic symptom relief, allergy prevention, or cancer treatment or prevention.
(6) The composition according to any one of (1) to (4), which is used for alleviating the symptoms of pollinosis.
(7) The composition according to any one of (1) to (4), which is for cancer treatment or prevention.
Is to provide.

By using the composition of the present invention, immunosuppression, allergic symptom relief, allergy prevention, or cancer treatment or preventive effect can be obtained. Further, as a further effect, the composition of the present invention can be expected to promote the colonization of lactic acid bacteria in the intestinal flora and continuously exert the above effect.

FIG. 1 is a flow chart showing a typical manufacturing process of the composition (liquid) of the present invention. FIG. 2 is a flow chart showing a typical manufacturing process of the composition (capsule) of the present invention. FIG. 3 is a graph showing the results of measuring the amount of IL-10 in the group to which the composition of the present invention was administered and the group to which fresh water was administered 37 days after the mice administered with the Sugi antigen and the adjuvant. FIG. 4 is a graph showing the results of measuring the amount of IL-4 after 37 days in the group to which the composition of the present invention was administered and the group to which fresh water was administered to the mice to which the Sugi antigen and the adjuvant were administered.

The present invention provides, in one embodiment, a composition comprising a fermented soybean lactic acid bacterium, a basidiomycete of the family Sparassis crispa and a basidiomycete of the family Hericiaceae.

The type of lactic acid bacterium used in this embodiment is not particularly limited, but is preferably a lactic acid bacterium belonging to the genus Lactobacillus. Examples of preferred Lactobacillus lactic acid bacteria are Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus bukunelli, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus del Bruecki, Lactobacillus fermentum, Lactobacillus. Lactobacillus Herveticas, Lactobacillus hirugardi, Lactobacillus Johnsony, Lactobacillus Reikmani, Lactobacillus lactis, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus ramnosus, Lactobacillus reuteri, Lactobacillus・ Sullivarius etc. can be mentioned. More preferred examples are Lactobacillus paracasei and Lactobacillus fermentum. The most preferred example is Lactobacillus paracasei. One type of these lactic acid bacteria may be used, or a plurality of types may be used. The origin of the lactic acid bacterium is not particularly limited, and examples thereof include intestinal lactic acid bacteria, animal-derived lactic acid bacteria, plant-derived lactic acid bacteria, and marine lactic acid bacteria. Preferably, the lactic acid bacterium used in this embodiment is of plant origin. The plant from which it is derived is not particularly limited, and examples thereof include vegetables such as cabbage, suguki, radish, carrot, and cucumber; fruits such as pineapple and persimmon; grains such as rice and wheat; and succulent plants such as aloe and cactus. The most preferable example in this embodiment is a lactic acid bacterium isolated from a persimmon.

In a specific embodiment, an example of the lactic acid bacterium in this embodiment is a lactic acid bacterium whose 16S rDNA has the sequence shown in SEQ ID NO: 1. In a more specific embodiment, the lactic acid bacterium in this embodiment has a 16SrDNA sequence having at least 75% sequence identity with the sequence set forth in SEQ ID NO: 1, such as at least 80%, at least 85%, at least 87%, at least 90. %, At least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, more specifically 90%, 91%, 92 %, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity.

The lactic acid bacterium used in this embodiment may contain a bacterium other than the genus Lactobacillus, or may be only a bacterium of the genus Lactobacillus. In addition, only lactic acid bacteria may be used for fermentation, or bacteria other than lactic acid bacteria may be used in combination if necessary.

The method for obtaining the lactic acid bacterium used in this embodiment is not particularly limited, and a commercially available product may be used. For example, it can be obtained from Daiwa Co., Ltd., Kaneka Corporation, Seti Co., Ltd., Toa Yakuhin Kogyo Co., Ltd., Toyo Shinyaku Co., Ltd., etc. Preferably, lactic acid bacteria of V-LAB stock solution (Daiwa Co., Ltd.) can be used.

The composition of this embodiment contains a lactic acid bacterium fermented product of soybean obtained by fermenting soybean with the above lactic acid bacterium. The soybean raw material used is not particularly limited, and all varieties of soybean can be used. Further, the soybean may be a full-fat soybean or a partially or completely defatted soybean. The form of the soybean raw material used in this embodiment is not particularly limited, and may be, for example, whole soybean, half-cracked soybean, grits, or powder. The soybean raw material used in this embodiment may be molted and / or hypocotyled, or may not be molted and / or hypocotyled.

The soybean raw material is typically washed, soaked in water or hot water, steamed and pulverized, and subjected to lactic acid bacteria fermentation. At the time of immersion, acids such as acetic acid, citric acid and hydrochloric acid, alkalis such as sodium hydroxide and baking soda, and / or salts such as sodium chloride and potassium chloride may be added.

The fermented lactic acid bacterium of soybean used in this embodiment may be a lactic acid bacterium fermented raw material obtained only from soybean, or a lactic acid bacterium fermented mixture of a mixture of raw materials other than soybean derived. In some cases, one or more assimilating sugars for assisting fermentation may or may not be contained. Examples of assimilating saccharides include glucose, fructooligo, sucrose, maltose, galactose, lactose, raffinose, trehalose, soybean oligosaccharide, fructooligosaccharide, xylooligosaccharide and the like. Examples of non-soy-derived ingredients include sweeteners, acidulants, seasonings, colorants, flavors, dietary fibers, stabilizers, antioxidants, thickeners, gelling agents, emulsifiers, surfactants, chelating agents, Examples include vitamins and spices. The amount of other raw materials added is not particularly limited and can be appropriately adjusted by those skilled in the art, but is preferably limited to a limit that does not interfere with the effects of the composition of this embodiment.

The obtained fermented soybean lactic acid bacterium may be used as it is as a raw material for the composition, or may be used after being dried once. When it is dried, it is preferable that it is not heated, for example, by freeze-drying.

The composition of this embodiment contains basidiomycetes of the family Sparassis crispa. The basidiomycetes of the family Sparassis crispa in this embodiment are not particularly limited, and examples thereof include Sparassis crispa, Sparassis cystidiosa, Sparassis miniensis, Sparassis spathulata, and Sparassis radicata. In one embodiment, the basidiomycete of the family Sparassis crispa in this embodiment is Sparassis crispa.

The composition of this embodiment contains basidiomycetes of the family Hericiaceae. The basidiomycetes of the Hericiaceae family in this embodiment are not particularly limited, and examples thereof include Hericiaceae, Hericiaceae, Hericiaceae, Hericiaceae, Hericiaceae, Hericiaceae, Hericiaceae, and Lion's mane. In one embodiment, the basidiomycete of the Hericium family in this embodiment is Lion's mane.

The form of the basidiomycete used in the composition of this embodiment is not particularly limited, and cells, chopped ones, powders, extracts and the like can be appropriately selected. Moreover, it may be a raw product or a dried product.

The content of the above-mentioned components in the composition of this embodiment is not particularly limited and can be appropriately adjusted. As an example, in terms of solid content, 5 to 85% by weight of soybean, more preferably 10 to 80% by weight, and 1 to 30% by weight of basidiomycetes of Hericiaceae, more preferably 5 to 25% by weight, are contained in the composition. , Basidiomycetes of the Hericiaceae family are contained in an amount of 1 to 30% by weight, more preferably 5 to 25% by weight.

The form of the composition of this embodiment is not particularly limited, and examples thereof include liquid, paste, powder, granular, solid, and gel. Since the action of the lactic acid bacterium itself is expected, it is preferable not to heat the lactic acid bacterium when it is dried, for example, by freeze-drying.

The composition of this embodiment may be prepared only from a fermented lactic acid bacterium of soybean, a basidiomycete of the family Sparassis crispa, and a basidiomycete of the family Hericiaceae. In some cases, one or more assimilating sugars for assisting fermentation may or may not be contained. Examples of assimilating saccharides include glucose, fructooligo, sucrose, maltose, galactose, lactose, raffinose, trehalose, soybean oligosaccharide, fructooligosaccharide, xylooligosaccharide and the like. Further, in the composition of this embodiment, other raw materials may or may not be added. Examples of other ingredients include sweeteners, acidulants, seasonings, colorants, flavors, dietary fibers, stabilizers, antioxidants, thickeners, gelling agents, emulsifiers, surfactants, chelating agents, vitamins, Examples include spices. The amount of other raw materials added is not particularly limited and can be appropriately adjusted by those skilled in the art, but is preferably limited to a limit that does not interfere with the effects of the composition of this embodiment.

^{The composition of this embodiment has a lactic acid bacterium density of at least 1 × 10 8} cfu / mL, preferably at least 1 × 10 ⁹ cfu / mL, more preferably by the action of soybeans, basidiomycetes of the family Hericiaceae, and basidiomycetes of the family Hericiaceae. Can be at least 1 × 10 ¹⁰ cfu / mL, and even more preferably at least 1 × 10 ¹¹ cfu / mL.

In another aspect, the present invention provides a method for producing a composition containing a fermented lactic acid bacterium of soybean, a basidiomycete of the family Sparassis crispa, and a basidiomycete of the family Hericiaceae.

The description of lactic acid bacteria, soybeans, basidiomycetes of the family Sparassis crispa, and basidiomycetes of the family Hericiaceae used in the method of this embodiment is as described above.

In the method of this embodiment, a soybean solution or slurry is prepared as one of the fermentation raw materials. As an example of a method for obtaining a slurry, there is a method in which water or warm water is added to raw soybeans, soaked for 10 to 30 hours, and then pulverized with a grinder or the like. At this time, the liquid portion may be separated before pulverization, and the liquid portion may be mixed again after pulverization. As another example, there is a method of dispersing beans crushed by a parvelizer or the like in water or warm water. For sterilization and enzyme inactivation of beans, it is preferable to perform heat treatment at the immersion stage and / or the slurry stage. The conditions of the heat treatment are not particularly limited and can be appropriately adjusted by those skilled in the art. As a specific example, it can be carried out at 90 to 120 ° C. for 1 to 5 hours, for example. The obtained slurry may be used as a fermentation raw material as it is, or the slurry may be subjected to solid-liquid separation such as centrifugation or filtration to recover only the liquid component and used as a fermentation raw material. In some cases, acids such as acetic acid, citric acid and hydrochloric acid, alkalis such as sodium hydroxide and baking soda, and / or salts such as sodium chloride and potassium chloride may be added to the water or hot water used for immersion or dispersion. It does not have to be added.

Fermentation conditions such as the amount of lactic acid bacteria added, the fermentation temperature, and the fermentation time in the method of this embodiment are not particularly limited and can be appropriately adjusted by those skilled in the art. Specific examples include, for example, 3 to 144 hours at 10 to 50 ° C., 24 to 120 hours at 15 to 45 ° C., 48 to 96 hours at 20 to 40 ° C., and the like. Prior to fermentation, assimilating sugars may be added as a nutrient source for lactic acid bacteria, if necessary. Examples of assimilating sugars are as described above. The amount of the assimilating sugar added is not particularly limited and can be appropriately adjusted by those skilled in the art. For example, 1 to 20% by weight, 5 to 10% by weight, etc. are mentioned with respect to the whole fermentation raw material. Moreover, it is not necessary to add the assimilating sugar.

In the method of this embodiment, the obtained fermented product may be used as it is as a fermented product of lactic acid bacteria of soybean. Further, dilution, concentration, drying and the like may be performed. When it is dried, it is preferably not heated, for example, by freeze-drying.

The composition of the present invention can be obtained by adding and mixing basidiomycetes of the family Sparassis crispa and basidiomycetes of the family Hericiaceae to the fermented lactic acid bacteria of soybean. The timing of adding the basidiomycetes of Sparassis crispa and the basidiomycetes of Hericiaceae is not particularly limited, and may be any of pre-fermentation, during fermentation, and after fermentation. For example, it may be added to the fermentation broth of soybean to continue the fermentation. In other examples, Sparassis crispa basidiomycetes and Hericiaceae basidiomycetes may be mixed with soybean solution or slurry prior to fermentation.

In the method of this embodiment, in addition to soybean, basidiomycete of Sparassis crispa, basidiomycete of Hericiaceae, lactic acid bacterium, and assimilating saccharide, other raw materials described above may or may not be added. Those skilled in the art can appropriately adjust the amount of addition and the timing of addition.

The composition of the present invention can be obtained by adding and mixing the basidiomycetes of Sparassis crispa and the basidiomycetes of Hericiaceae to the fermented lactic acid bacteria of dried soybean. Further, in the case of adding basidiomycetes of Sparassis crispa and basidiomycetes of Hericiaceae to soybean and then fermenting with lactic acid bacteria, when the obtained fermented product is used as it is, it is preferable to cool it quickly. The cooling temperature is 10 ° C. or lower, for example, -2 to 10 ° C. The composition obtained by the method of this embodiment is preferably stored in a refrigerator. Further, dilution, concentration, drying and the like may be performed. When it is dried, it is preferably not heated, for example, by freeze-drying.

In another aspect, the present invention provides a pharmaceutical composition containing a fermented soybean lactic acid bacterium, a basidiomycete of the family Sparassis crispa, and a basidiomycete of the family Hericiaceae as active ingredients. In another aspect, a method for producing the pharmaceutical composition is provided.

In this embodiment, the above composition may be used as it is as a pharmaceutical composition. Alternatively, the above composition may be formulated according to a conventional method (see, for example, Remington's Pharmaceutical Science, latest edition, Mark Publishing Company, Easton, USA), including both pharmaceutically acceptable carriers and additives. There may be. For example, surfactants, excipients, colorants, flavoring agents, preservatives, stabilizers, buffers, suspending agents, tonicity agents, binders, disintegrants, lubricants, fluidity promoters, flavoring agents. However, the present invention is not limited to these, and other commonly used carriers can be appropriately used. Specifically, light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carmellose calcium, carmellose sodium, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl acetal diethylaminoacetate, polyvinyl pyrrolidone, gelatin, medium chain fatty acid triglyceride, Examples thereof include polyoxyethylene hydrogenated castor oil 60, sucrose, carboxymethyl cellulose, corn starch, and inorganic salts.

Examples of the method for administering the pharmaceutical composition of this embodiment include oral administration and parenteral administration, and specific examples of such administration methods include injection administration, nasal administration, pulmonary administration, and transdermal administration. As an example of injection administration, the pharmaceutical composition of this embodiment can be administered systemically or locally, for example, by intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, or the like. Preferably, the method of administration of the pharmaceutical composition of this embodiment is oral administration. The form of the pharmaceutical composition of this embodiment is not particularly limited, and examples thereof include concentrates, powders, granules, tablets, tablets, capsules, and drinks.

The subject of administration of the pharmaceutical composition of this embodiment includes humans, animals including humans, and animals not containing humans, for example, humans, mice, rats, monkeys, pigs, cows, horses, goats, sheep, donkeys, etc. Examples include, but are not limited to, dogs, cats, rabbits, hamsters, guinea pigs, chickens, and other livestock, poultry, and pet animals.

The pharmaceutical composition of this embodiment may be administered three times a day, twice a day, or once a day. Also, for example, the subject may be administered with the pharmaceutical composition of this embodiment at each meal or before or after, or once daily, for example, at breakfast or before or after, at lunch or before or after. , The pharmaceutical composition of this embodiment may be administered at or before or after dinner. Moreover, you may administer the pharmaceutical composition of this embodiment between meals.

The dose of the pharmaceutical composition of this embodiment can be appropriately adjusted according to the disease and is not particularly limited. Examples of the dose include, in terms of solid content, about 0.3 g or more, about 1 g or more of the composition per adult per day, and the like.

The pharmaceutical composition of this embodiment can be used for immunosuppression, allergic symptom relief, allergy prevention, or cancer treatment. Examples of allergies include atopic dermatitis, bronchial asthma, allergic rhinitis, food / drug / metal allergies, and the like. As a more specific example, this composition can be used for alleviating and preventing pollinosis symptoms. In addition, the pharmaceutical composition of this embodiment can be expected to promote the colonization of lactic acid bacteria in the intestinal flora and continuously exert the above effects.

Examples of cancers in this embodiment are malignant melanoma, skin cancer, lung cancer, tracheal and bronchial cancer, oral epithelial cancer, esophageal cancer, gastric cancer, colon cancer, rectal cancer, colon cancer. , Liver and intrahepatic bile duct cancer, kidney cancer, pancreatic cancer, prostate cancer, breast cancer, uterine cancer, ovarian cancer, brain tumor and other cancers / tumors with malignant epithelial cells, myoma, Cancers / tumors in which muscles and bones that make up supporting tissues such as osteosarcoma and Ewing sarcoma have become malignant, and cancers / tumors derived from hematopoietic cells such as leukemia, malignant lymphoma, myeloma, and Berkit lymphoma Can be mentioned.

In another aspect, the present invention provides a food containing a fermented soybean lactic acid bacterium, a basidiomycete of the family Sparassis crispa, and a basidiomycete of the family Hericiaceae. Further, in another aspect, a method for producing the food is provided.

In this embodiment, the above composition may be used as it is as a food. In addition, the carriers and additives mentioned in the above pharmaceutical compositions may be included. The form of the food of this embodiment is not particularly limited, and examples thereof include concentrates, powders, granules, tablets, tablets, gums, candies, capsules, pastes, jellies, and drinks. Further, the above composition may be added to other foods as it is or in the form of a concentrate, powder, granules, paste or the like. Further, the above composition may be used as it is, or in a state of a concentrate, powder, granule, paste or the like, and if necessary, other raw materials may be added and used as a food additive.

Examples of other raw materials that may be contained in the food of this embodiment are seasonings such as sugar, salt, soy sauce, miso, vinegar; ^{sweeteners such as honey, maple syrup, sclarose registered trademark} , acesulfam potassium, aspartame; Acids such as acid, malic acid, tartaric acid, acetic acid; bitterness such as caffeine, narringine; spices such as oregano, pepper, cinnamon, ginger, turmeric, chili, basil, paprika, wasabi; salad oil, sesame oil, saflower oil , Sunflower oil, rapeseed oil, fish oil, beef fat, pork fat, etc .; flavor oil; yeast extract, seafood extract, beef extract, pork extract, chicken extract and other extracts; fruit juice; vegetable juice; vitamins; minerals; sugars; oligosaccharides ; Polysaccharides; dietary fiber; amino acids; peptides; fatty acids; coenzymes; flavors; emulsifiers; thickeners; color formers and the like.

The food of this embodiment may be ingested three times a day, twice a day, or once a day. In certain embodiments, the food of this embodiment may be ingested as a functional food, eg, at each meal or before or after, or once daily, eg, at breakfast or before or after, at lunch or above. It may be taken before or after, at dinner or before or after. It may also be taken between meals.

The intake of the food of this embodiment can be appropriately adjusted according to the product design and is not particularly limited. Examples of preferred intakes are, for example, 5 to 100 ml, 10 to 75 ml, 20 to 60 ml, 40 to 60 ml, etc. of the composition per day for adults.

The food of this embodiment can be expected to have effects such as immunosuppression, allergic symptom relief, and allergy prevention. Examples of allergies include atopic dermatitis, bronchial asthma, allergic rhinitis, food / drug / metal allergies, and the like. As a more specific example, this composition can be used for alleviating and preventing pollinosis symptoms. In addition, the food of this embodiment can be expected to promote the colonization of lactic acid bacteria of OTU520 in the intestinal flora and continuously exert the above effects. The ingestion target of the food of this embodiment is not particularly limited, and can be widely used by infants, adults, the elderly and the like.

Hereinafter, embodiments of the present invention will be described in more detail with reference to Examples.

Example 1: Identification of plant-derived lactic acid bacteria 16S rDNA analysis was performed on lactic acid bacteria isolated from persimmons of early-maturing sword roots. The sequence of the obtained 16SrDNA is shown in Table 1.

This sequence showed 100% compatibility with the Lactobacillus paracasei subsp. Paracasei JCM8130 strain, and this lactic acid bacterium was identified as Lactobacillus paracasei. Further, since the theoretical value of OTU is 517 bp from the base sequence, it is included in the range of OTU520. The OTU (Operational Taxonomic Unit) means a classification unit in T-RFLP analysis, and refers to a unit corresponding to the type of fungus (see JP-A-2012-165716). The lactic acid bacterium of OTU520 refers to a so-called good bacterium group including Lactobacillus, Streptococcus, Enterococcus, etc. in the human intestinal bacterium classification group (for example, URL: https://www.tecsrg.co.jp/). See t-rflp/tree_html/lactobacillales_520.html).

Example 2: Preparation of composition (liquid) After washing the whole soybean with water, 3 times the amount of water was added, the mixture was immersed for 15 hours, and then heated to 100 ° C. and boiled for 3 hours. The treated product was filtered, and Vitamin C, Lion's mane, and Sparassis crispa were added to the filtrate and mixed. The filtration residue was milled to separate soybean meal and then added to the mixture. The resulting mixture was sterilized under high pressure at 121 ° C. for 20 minutes and cooled to 35 ° C. The lactic acid bacterium obtained in Example 1 was added, and the mixture was cultured at 30 ° C. for 24 hours and then filled in a container to obtain the composition (liquid) of the present invention. The composition of this composition is shown in Table 2.

Example 3: Preparation of composition (capsule) The whole soybean was washed with water, three times the amount of water was added, acetic acid was further added to pH 4.0, and the soybean was immersed in a refrigerator overnight. After draining, it was steamed at 100 ° C. for 1 hour in a steamer, pulverized with a meat chopper (φ5 mm), and cooled to 35 ° C. The lactic acid bacteria and sugars obtained in Example 1 were added, cultured at 30 ° C. for 24 hours, freeze-dried, and pulverized to obtain a powder of a fermented soybean lactic acid bacterium. Sparassis crispa powder, Lion's mane powder, and other ingredients were added thereto and filled into capsules to obtain the composition (capsule) of the present invention. The composition of this composition is shown in Table 3.

Example 4: Confirmation of allergy-suppressing effect Mice were divided into two groups, one group was ingested with the composition obtained in Example 2, and the other group was ingested with fresh water for 37 days. Both groups received intraperitoneal purified cedar pollen antigen and adjuvant (1 μg, once weekly x 3 times, and 0.2 μg nasal drops once daily x 7 days for sneezing test). The IL-10 and IL-4 concentrations in the blood were measured by the ELISA method 37 days after the start of ingestion. The results are shown in FIGS. 3 and 4. In the group ingesting the composition of the present invention, the amount of cytokine IL-10 that suppresses pollinosis was significantly high, and the amount of cytokine IL-4 that exacerbated pollinosis was significantly low.

Example 5: Changes in intestinal flora by the composition of the present invention The mice were divided into three groups, and the composition of Example 3 was used as a normal breeding group, a group fed with a sterilized MF feed (Oriental yeast), and an administration group. , The group in which 8 tablets of 5.5 g tablets were given per day instead of capsules, and as a control group, the fermented soybean powder of the composition of Example 3 was replaced with soybean powder, and Hanabira bamboo powder and Yamabushitake powder were not added. Tablets were prepared and used as a group in which 8 tablets were given per day. Fecal feed was collected from each mouse before the start of the experiment (day 0) and at the time when 4 weeks had passed (day 28), and analysis was performed by the T-RFLP method / Nagashima method. The peak area ratio of each OTU in the Gut microbiota taxon was compared.

When the peak area ratio of each OTU for each individual mouse was calculated, OTU520 Lactobacillales, which was not detected on day0, was detected in 8 out of 10 mice on day28 of the administration group. This newly detected bacterial group of OTU520 corresponds to the lactic acid bacterium contained in the composition of the present invention, and it is considered that it was taken up by the mouse by ingestion of the composition of the present invention. It was considered that the composition of the present invention allows plant-derived lactic acid bacteria to reach the intestine alive and efficiently colonize the intestinal flora.

Example 6: Effects on allergy index and tumor marker For adults, allergy index (IgE, View allergy 39 items) and tumor marker (CEA, TPA, CA15-3, CA19-9, CA125, HER2 protein mass, ICTP, PSA) was examined, subjects with allergic diseases or tumor markers above the reference value were selected, the composition of Example 3 was distributed once every three months, and follow-up and examination were performed. Improvements in allergy index values and tumor marker values indicate that they have allergic symptom relief and cancer therapeutic effects, respectively.

The compositions of the present invention provide immunosuppressive, allergic symptom relief, allergy prevention, or cancer therapeutic or prophylactic effects. In addition, the composition of the present invention can be expected to promote the colonization of lactic acid bacteria in the intestinal flora and continuously exert the above effects.

Claims (7)

A composition comprising a fermented soybean lactic acid bacterium, a basidiomycete of the Sparassis crispa family, and a basidiomycete of the Hericiaceae family. The composition according to claim 1, wherein the basidiomycete of the family Sparassis crispa is Sparassis crispa, and the basidiomycete of the family Hericiaceae is Lion's mane. The composition according to claim 1 or 2, wherein the lactic acid bacterium is a persimmon-derived lactic acid bacterium. The composition according to any one of claims 1 to 3, wherein the lactic acid bacterium is Lactobacillus paracasei. The composition according to any one of claims 1 to 4, which is for immunosuppression, for allergic symptom relief, for allergy prevention, or for cancer treatment or prevention. The composition according to any one of claims 1 to 4, which is used for alleviating the symptoms of pollinosis. The composition according to any one of claims 1 to 4, which is used for cancer treatment or prevention.

Images